Turoctocog alfa pegol

Drug Profile

Turoctocog alfa pegol

Alternative Names: Long acting recombinant factor VIII - Novo Nordisk; N8-GP; N8-GP rFVIII; NN-7088; NNC-0129-0000-1003; PEG turoctocog alfa; Pegylated turoctocog alfa; Recombinant factor VIII long acting - Novo Nordisk; rFVIII glycopegylated - Novo Nordisk

Latest Information Update: 20 May 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Novo Nordisk
  • Class Antihaemorrhagics; Blood coagulation factors; Polyethylene glycols; Recombinant proteins
  • Mechanism of Action Blood coagulation factor replacements; Factor X stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Haemophilia A

Most Recent Events

  • 07 Apr 2017 Novo Nordisk completes the phase I pathfinder™7 trial for Haemophilia A (In adolescents, In adults) in USA, Denmark, Germany, Netherlands, Spain and France (IV) (NCT02920398)
  • 09 Feb 2017 Novo Nordisk has patent protection for turoctocog alfa pegol in USA, EU and Japan
  • 09 Feb 2017 Novo Nordisk announces intention to submit regulatory applications to USA and EU for Haemophilia A in 2018 (Novo Nordisk form 20-F, February 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top